Pregabalin Capsule
Product Images NDC 71335-1300

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1300). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl7133513002

This is a packaging label for a medication called "Lyrica 50mg (CV)" manufactured by Laurus Labs Limited. It comes in a capsule form and is packed by Bryant Ranck Prepack. The label also includes the dosage, the expiration date, the NDC number, and the storage information. There is a warning to keep the medication out of reach of children.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

The text seems to be showing data related to the percentage of patients improved and the percentage improvement in pain from baseline. However, the formatting is not clear and some characters are not readable, making it difficult to provide an accurate description.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

The text is describing a table showing the percent improvement in pain from baseline among patients, after taking Pregabalin 160 mg for three days. The table contains percentages ranging from 2% to 100%. There are also some numerical values, but their meaning is unclear. The text is not available and does not provide additional information about the context of the table.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

This appears to be a chart showing different medications and the percentage of patients who experienced improvement in pain. The medications listed include pregabalin at various doses and frequencies. However, the chart is not entirely clear and there are some missing values.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

This is a clinical trial report comparing the effectiveness of Fregabalin (100mg, three times a day) and Pregabalin (80mg, three times a day) with a Placebo drug. The improvement of patients was measured using a scale, and the percentage of patients who improved through the treatment was reported. There is also a chart showing percentages of improvements in pain levels from the baseline among treated patents.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

This appears to be a chart displaying different doses of medication (Pregabalin) and a placebo in terms of their effects on pain. It shows the percent of patients and percent improvement in pain from baseline for each dose. However, the text is difficult to read and there are errors in the spelling of the medication name.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

This is a partial data table with information on estimated percentage of subjects without LTR (likely to return) for a study comparing Pregabain and Plcebo. There are different percentages presented for each treatment, but no explanation or context is given for these results. The table also includes an indication of days, but it's not clear how these correspond to the percentages presented.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.